MILAN (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that it will present new preliminary data from the Phase I/II TEM-GBM study of Temferon™ in patients
MILAN (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that it will present new preliminary data from the Phase I/II TEM-GBM study of TemferonTM in patients
MILANO (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), today announced that Pierluigi Paracchi, Founder, Chairman and CEO of Genenta, will be presenting a corporate
MILANO (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that they will present the corporate overview at the ACCESS CHINA Forum 2020, Summer Online Partnering
MILANO (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that they presented preliminary pre-clinical and clinical data from the TEM-GBM_001 clinical trial at
MILANO (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that they will present preliminary pre-clinical and clinical data from the TEM-GBM_001 clinical trial
MILANO (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that they presented preliminary clinical data from the TEM-GBM_001 clinical trial at the following
FOSHAN & BEIJING (China) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that they won the first prize at the BSSEC, China-Italy Best Start Up Showcase and Entrepreneurship Competition
MILANO (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem cell gene therapies for cancer (Temferon™), today announced that the Company is scheduled to present at: NUO Capital Event in Hong Kong on Nov 12 at
ROME (Italy) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), today announced that won the first prize at the BSSEC, China-Italy Best Start Up Showcase and Entrepreneurship Competition 2018/2019.
